EDGAR Filing Documents for 0001640334-20-000917

Form F-3/A - Registration statement by foreign private issuers: [Amend]

SEC Accession No. 0001640334-20-000917

Filing Date

2020-04-24

Accepted

2020-04-24 17:15:00

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	FORM F-3/A	nymx_f3a.htm	F-3/A	249265
2	EX-5.1	nymx_ex51.htm	EX-5.1	23338
3	EX-10	nymx_ex10.htm	EX-10	290068
4	EX-23.1	nymx_ex231.htm	EX-23.1	1863
5		nymx_f3aimg1.jpg	GRAPHIC	7691
6		nymx_ex231img1.jpg	GRAPHIC	10065
	Complete submission text file	0001640334-20-000917.txt		590254

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: F-3/A | Act: 33 | File No.: 333-237564 | Film No.: 20816028
SIC: 2835 In Vitro & In Vivo Diagnostic Substances